Essay On Glioblastoma Multiforme

2535 Words6 Pages

Introduction:
Glioblastoma Multiforme (GBM) is known as the most aggressive form of malignant brain tumor in adults [1,2,4,5]. Patients who are diagnosed with Glioblastoma Multiforme have an extremely poor rate of survival. Glioblastoma multiforme has been found to be sporadic and doesn’t have any linkage or genetic pre-dispositions. The prognostic of GBM is poor and there has been little improvement of the patients overall survival rates for the past three decades [5]. Although patients undergo surgical resection along with chemotherapy and high-dose radiotherapy the survival rate after diagnosis is still low at the survival time of 14-15.5months [1,2,4,5]. There has been hope that immunotherapy may contribute as a beneficial treatment to this malignant brain tumor [1]. Treatments that would be effective in GBM patients are desperately needed. Three studies were reviewed to get a better understanding of what treatments or combination of treatments would be more beneficial to GBM patients.
The first experiment reviewed was titled “MRP3: a molecular target for human glioblastoma multiforme immunotherapy” and was carried out at Duke University Medical Center in Durham, North Carolina by-Kuan et al’s (2010). Their study was conducted to identify brain tumor markers that are needed for prognostics from immunotherapeutic approaches. From series of analysis they found multidrug-resistance protein 3 (MRP3) to be a candidate marker of GBM [2]. After discovering a potential molecular therapeutic target Kuan et al. hypothesize that there would be evidence that MRP3is potentially a good target in immunotherapy for those with GBM [2].
In the second experiment was titled, “Prognostic factors in glioblastoma multiforme patients receiving ...

... middle of paper ...

...e level for the high dose radiotherapy protocol. Also, the observations shows that patients that survive the treatments should be watched over a longer follow-up time [5].
Heimberger et al., (2007) results implicated that producing T cells affected by the vaccination did not decrease when temozolomide was given concurrently [1]. Also after the third vaccination there was an increase in response to PEPvIII-specific IgG while temozolomide was given simultaneously. After following the CD8+ T cell Heimberger et al. was able to identify a window where the CD8+ T cell is responsive with the decline of T regs [1]. This confirms that during immunization temozolomide does not decrease the immune response. “The delay of T reg response would allow for efficacious immune responses but eventual down-modulation/ regulation of this response” [1].
After analyzing and reviewing

Open Document